Home > Oncology > ASCO 2019 > Lung Cancer > Lurbinectedin Shows Promise as Second-line Therapy for SCLC

Lurbinectedin Shows Promise as Second-line Therapy for SCLC

Presented By
Dr Luis G. Paz-Ares, Hospital Universitario 12 de Octubre, Spain
Conference
ASCO 2019

Medical writer: Tim Donald, ELS

Lurbinectedin, an inhibitor of activated transcription, showed notable anti-tumour activity as a second-line treatment in small cell lung cancer (SCLC) in a phase II clinical trial, according to a June 1 presentation (Abstract 8506).

“Lurbinectedin is an active single agent in second-line SCLC,” said presenter Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, CNIO, and Universidad Complutense and Ciberonc, Spain. “Anti-tumour activity has been observed in sensitive patients, with an overall response rate [ORR] of 45%. But also, in a setting where we have very few opportunities for treatment, in the setting of resistance, with ORR of 22.2%.”

In addition, the safety profile was favorable, and side effects were easily managed, he said. There were low percentages of treatment-related serious adverse events (SAEs) and of discontinuation due to adverse events (AEs), and there were no toxic deaths.

“W...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on